CGAS, cyclic GMP-AMP synthase, 115004

N. diseases: 40; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0041296
Disease: Tuberculosis
Tuberculosis 		0.040 Biomarker disease BEFREE We demonstrate that the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) is essential for initiating an IFN response to Mtb infection. cGAS associates with Mtb DNA in the cytosol to stimulate cyclic GAMP (cGAMP) synthesis. 26048138 2015
CUI: C0041296
Disease: Tuberculosis
Tuberculosis 		0.040 Biomarker disease BEFREE This study provides new insight into the interaction between cGAS and dendritic cells (DCs), which could be considered in the development of new drugs and vaccines against tuberculosis. 30791397 2019
CUI: C0041296
Disease: Tuberculosis
Tuberculosis 		0.040 Biomarker disease BEFREE Cyclic GMP-AMP Synthase Is an Innate Immune DNA Sensor for Mycobacterium tuberculosis. 26048137 2015
CUI: C0041296
Disease: Tuberculosis
Tuberculosis 		0.040 GeneticVariation disease BEFREE We found that the rs311686 SNP upstream of cGAS provides protection from getting TB overall and is differently distributed in pulmonary TB patients compared with extra-pulmonary and particularly relapse cases. 31118495 2020
CUI: C0024141
Disease: Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic 		0.030 Biomarker disease BEFREE Increasing evidence indicates that the cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING) signaling pathway has a critical pathogenic role in systemic lupus erythematosus (SLE). 29806091 2018
CUI: C0024141
Disease: Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic 		0.030 Biomarker disease BEFREE Inappropriate stimulation of cGAS has been implicated in autoimmune disease such as systemic lupus erythematosus, thus inhibition of cGAS may be of therapeutic benefit in some diseases; however, the size and polarity of the cGAS active site makes it a challenging target for the development of conventional substrate-competitive inhibitors. 28934246 2017
CUI: C0024141
Disease: Lupus Erythematosus, Systemic
Lupus Erythematosus, Systemic 		0.030 AlteredExpression disease BEFREE Expression of cGAS in peripheral blood mononuclear cells (PBMCs) was significantly higher in SLE patients than in normal controls (n = 51 and n = 20 respectively; P < 0.01). 27863149 2017
CUI: C0393591
Disease: AICARDI-GOUTIERES SYNDROME
AICARDI-GOUTIERES SYNDROME 		0.030 Biomarker disease BEFREE These findings implicate cGAS as a key driver of autoimmune disease and suggest that cGAS inhibitors may be useful therapeutics for Aicardi-Goutières syndrome and related autoimmune diseases. 26223655 2015
CUI: C0393591
Disease: AICARDI-GOUTIERES SYNDROME
AICARDI-GOUTIERES SYNDROME 		0.030 AlteredExpression disease BEFREE We find that a chemically improved member, RU.521, is active and selective in cellular assays of cyclic GMP-AMP synthase-mediated signaling and reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome. 28963528 2017
CUI: C0393591
Disease: AICARDI-GOUTIERES SYNDROME
AICARDI-GOUTIERES SYNDROME 		0.030 Biomarker disease BEFREE A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus. 27863149 2017
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.020 Biomarker disease BEFREE Animals lacking cyclic GMP-AMP synthase display significantly improved early survival after myocardial infarction and diminished pathological remodeling, including ventricular rupture, enhanced angiogenesis, and preserved ventricular contractile function. 29437120 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.020 AlteredExpression disease BEFREE Mice genetically deficient in cyclic GMP-AMP synthase (cGAS), its adaptor STING, IRF3, or the type I IFN receptor IFNAR exhibited impaired interferon-stimulated gene (ISG) expression and, in the case of mice deficient in IRF3 or IFNAR, improved survival after MI as compared to controls. 29106401 2017
CUI: C0011311
Disease: Dengue Fever
Dengue Fever 		0.010 Biomarker disease BEFREE Our data demonstrate a mechanism by which cGAS senses cellular damage upon DENV infection. 28346446 2017
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute 		0.010 AlteredExpression disease BEFREE Cisplatin induced mtDNA leakage into the cytosol-probably through BCL-2-like protein 4 (BAX) pores in the mitochondrial outer membrane-in tubules, with subsequent activation of the cGAS-STING pathway, thereby triggering inflammation and AKI progression, which is improved in STING-deficient mice. 31665638 2019
CUI: C0023418
Disease: leukemia
leukemia 		0.010 Biomarker disease BEFREE Importantly, we demonstrate using mice lacking DDX41 or cGAS that both sensors are needed for the full antiviral response needed to control <i>in vivo</i> MLV infection. 29871919 2018
CUI: C0024131
Disease: Lupus Vulgaris
Lupus Vulgaris 		0.010 Biomarker disease BEFREE A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus. 27863149 2017
CUI: C0024138
Disease: Lupus Erythematosus, Discoid
Lupus Erythematosus, Discoid 		0.010 Biomarker disease BEFREE A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus. 27863149 2017
CUI: C0024530
Disease: Malaria
Malaria 		0.010 Biomarker disease BEFREE We used a nonlethal murine model of malaria (Plasmodium yoelii 17XNL) to assess the contribution of the pattern recognition receptor cyclic GMP-AMP synthase (cGAS) to the development of humoral immunity. 29367469 2018
CUI: C0024793
Disease: Marek Disease
Marek Disease 		0.010 Biomarker disease BEFREE This study demonstrates that the cGAS-STING DNA-sensing pathway is critical for the induction of the IFN-β response against MDV infection in chicken fibroblasts and macrophages. 30518647 2019
CUI: C0036220
Disease: Kaposi Sarcoma
Kaposi Sarcoma 		0.010 Biomarker disease BEFREE This review summarizes the evasion strategies of host cGAS DNA sensing pathway by Kaposi's Sarcoma-associated Herpesvirus (KSHV) and their contributions to KSHV life cycles. 27933565 2016
CUI: C0349204
Disease: Nonorganic psychosis
Nonorganic psychosis 		0.010 Biomarker disease BEFREE Probands manifested severe impairment (CGAS 43.9 +/- 8.9), elated mood (84.8%), grandiosity (78.3%), rapid cycling (78.3%) and psychosis (63.0%). 10331118 1999
CUI: C0409974
Disease: Lupus Erythematosus
Lupus Erythematosus 		0.010 Biomarker disease BEFREE A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus. 27863149 2017
CUI: C0518948
Disease: Chlamydia trachomatis infection
Chlamydia trachomatis infection 		0.010 AlteredExpression disease BEFREE These novel findings provide evidence that cGAS-mediated DNA sensing directs IFN-β expression during Chlamydia trachomatis infection and suggest that effectors from infected cells can directly upregulate IFN-β expression in adjacent uninfected cells during in vivo infection, contributing to pathogenesis. 25070851 2014
CUI: C1332977
Disease: Childhood Leukemia
Childhood Leukemia 		0.010 Biomarker disease BEFREE Importantly, we demonstrate using mice lacking DDX41 or cGAS that both sensors are needed for the full antiviral response needed to control <i>in vivo</i> MLV infection. 29871919 2018
CUI: C1536085
Disease: Geographic Atrophy
Geographic Atrophy 		0.010 AlteredExpression disease BEFREE Moreover, caspase-4, gasdermin D, interferon-β, and cGAS levels were elevated in the RPE in human eyes with geographic atrophy. 29176737 2018